Greinwald, Roland

norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis

Fickert, P., Hirschfield, G. M., Denk, G., Marschall, H.-U., Altorjay, I., Färkkilä, M., Schramm, C., Spengler, U., Chapman, R., Bergquist, A., et al. (2017) · Journal of Hepatology

Liver Diseases and ImmunityInflammatory Bowel Disease

Cited by 297

A placebo-controlled randomised trial of budesonide for PBC following an insufficient response to UDCA

Hirschfield, G. M., Beuers, U., Kupcinskas, L., Ott, P., Bergquist, A., Färkkilä, M., Manns, M. P., Parés, A., Spengler, U., Stiess, M., et al. (2021) · Journal of Hepatology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 108

Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial

Traussnigg, S., Schattenberg, J. M., Demir, M., Wiegand, J., Geier, A., Teuber, G., Hofmann, W. P., Kremer, A. E., Spreda, F., Kluwe, J., et al. (2019) · The Lancet Gastroenterology & Hepatology

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 88

A Randomised, Double-blind, Placebo-controlled Trial of Trichuris suis ova in Active Crohn’s disease

Schölmerich, J., Fellermann, K., Seibold, F. W., Rogler, G., Langhorst, J., Howaldt, S., Novacek, G., Petersen, A. M., Bachmann, O., Matthes, H., et al. (2016) · Journal of Crohn's and Colitis

Inflammatory Bowel DiseaseParasites and Host Interactions

Cited by 66

Challenges and opportunities in IBD clinical trial design

Dubinsky, M. C., Collins, R., Abreu, M. T., Abreu, M. T., Collins, R., Dubinsky, M. C., Jairath, V., Lewis, J. D., Lindsay, J., Merad, M., et al. (2021) · Gastroenterology

Inflammatory Bowel DiseaseStatistical Methods in Clinical Trials

Cited by 34